Hemogenyx Pharmaceuticals Share Discussion Threads

[justaman] 11/1/2022 00:19

The sad thing is, if one was to believe this to be reality (which it isn't) that someone with so much would have such a lonely and sad existence and spend so much of his time doing so little in the world. I really do feel for you Badger. Irrespective of how much you fantasise about having... if you carry on the way you are in life you'll never have happiness.

[davevtsmummy] 10/1/2022 21:58

Badger is a bit of a dreamer...probably lives in a thai brothel.

[badger60] 10/1/2022 18:06

Pikey....and it's also 5 houses...

[checkricky] 10/1/2022 15:23

BLAGGER60 DO YOU JUST WANT TO GO BACK AND CHECK I DON'T WANT YOU GETTING YOUR NUMBERS MIXED UP YOU KNOW £2 MIL IN THE BANK AND MAKING £450K AND ALL THAT blag LOL :))))

[checkricky] 10/1/2022 14:27

my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

[checkricky] 10/1/2022 14:26

To stay up to date you can register with the link below for the H.C. Wainwright BIOCONNECT Virtual Conference Starts this Monday 10th January till the 13th January 2022

my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

As per last RNS:
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022.


As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates to conference attendees.

If you are an institutional investor and would like to listen to the Company's presentation, please click on the following link to register for the conference: hxxps://hcwevents.com/bioconnect/.

The conference will feature corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.


Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Bioconnect Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases."

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.



The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.



For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.


About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

[badger60] 10/1/2022 12:38

From LSE...



Pikey....This link works.....

[badger60] 10/1/2022 12:31

Pikey really should stick to what he's good at which is.............nicking car wheels, threatening bb posters with violence and slapping his missus about........

[badger60] 10/1/2022 12:15

That's 9 times now!!!

[checkricky] 10/1/2022 12:10

To stay up to date you can register with the link below for the H.C. Wainwright BIOCONNECT Virtual Conference Starts this Monday 10th January till the 13th January 2022

hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

As per last RNS:
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022.


As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates to conference attendees.

If you are an institutional investor and would like to listen to the Company's presentation, please click on the following link to register for the conference: hxxps://hcwevents.com/bioconnect/.

The conference will feature corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.


Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Bioconnect Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases."

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.



The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.



For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.


About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

[badger60] 10/1/2022 11:59

philipw1

Have a gander at some of Pikey's previous ADVFN posts if you want bad language.....

Jhfh
Still spouting drivel next door ,I see....

[philipw1] 10/1/2022 11:53

I am not in the slightest surprised that he has profiles on twitter, if he behaves like this on ADVFN it is probably safe to assume he is at it on the other platforms aswell, although I am not aware of any other platform allowing the sort of language and behaviour which is tolerated here.

[badger60] 10/1/2022 11:52

You don't work for Spangles with Pikey as well, do you?

[justaman] 10/1/2022 11:39

Lol. Clueless.

[badger60] 10/1/2022 11:37

Lunus1Hi mate. Come back soon ffs, the Pikey is a complete BB posting embarrassment for the company.........the same as MadVlad is when he opens his mouth publicly......

[badger60] 10/1/2022 11:21

Pikey....next stop 1.80p bid .... especially when MadVlad opens his gob........